Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21

• https://twitter.com/synovialjoints/status/1800915408175927352/photo/1

Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz

• https://twitter.com/synovialjoints/status/1800913941041967564/photo/1

In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o

• https://twitter.com/synovialjoints/status/1800910597405782403/photo/1
• https://twitter.com/synovialjoints/status/1800910597405782403/photo/1

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1
• https://twitter.com/DrMiniDey/status/1800883089377562909/photo/1

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6

• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1
• https://twitter.com/synovialjoints/status/1800879381436674257/photo/1